Prywatna Klinika Połozniczo-Ginekologiczna Sp z o.o.
Bialystok, 15-224, Poland
NCT Number: NCT01630252
This is a prospective, three-part (Part A1, Part A2 and Part B),Phase II study investigating the efficacy, safety, pharmacokinetics and pharmacodynamics of the JNK inhibitor PGL5001 orally administered for up to 5 months with concomitant DMPA administration for the treatment of laparoscopically diagnosed inflammatory endometriosis. The part A1 is open-label, the parts A2 and B are double-blind.
The target population will be women of reproductive age and suffering from newly diagnosed peritoneal and/or ovarian endometriosis.
Looking for future studies?
Notify Me18 year and older
Female
Interventional
Phase 2
Bialystok, 15-224, Poland
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
PGL5001 320mg/day (160 mg twice a day) for 8 weeks + one unique DMPA 150 mg injection
PGL5001 matching placebo (twice a day) for 8 weeks + one unique DMPA 150 mg injection
Time frame: at week 8, week 20
Looking for future studies?
Notify MePregLem SA
Industry
A Phase IIa Efficacy and Safety Study of PGL5001 Versus Placebo Administered for up to 5 Months With Concomitant Administration of Depot Medroxyprogesterone Acetate for the Treatment of Peritoneal and/or Ovarian Endometriosis With an Inflammatory Component.
Acronym: JADE
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06660043
Endometriosis, Female Urogenital Diseases
Chevry-Cossigny, France
View Trial DetailsNCT06215937
Endometriosis, Female Urogenital Diseases
Vancouver, British Columbia, Canada
View Trial DetailsNCT07800442
Disease, Endometriosis
Warsaw, Poland
View Trial DetailsNCT07202741
Endometriosis, Female Urogenital Diseases
Istanbul, Turkey (Türkiye)
View Trial Details